List view / Grid view
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The Australian Therapeutic Goods Administration (TGA) has granted orphan drug designation to Santhera Pharmaceutical’s idebenone (raxone) for the treatment of Duchenne muscular dystrophy (DMD). The product has already received ODD from European, Swiss and US authorities...
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The effects of lorediplon (5 and 10 mg) are being compared to both placebo and zolpidem. The aim of the study is to evaluate the appropriate effective dose of lorediplon, to further characterise its efficacy on sleep maintenance/sleep quality and to evaluate any next day hangover effects in adult patients…
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The discoveries include DNA changes in three rare genes that have much larger effects on blood pressure in the population than previously seen, providing new insights into the physiology of hypertension and suggesting new targets for treatment...
8 September 2016 | By Coulter Partners
Coulter Partners was delighted to partner with Erytech Pharma to secure the appointment of Allene M. Diaz to its Board of Directors as a nonvoting member (censeur)...
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The coil is the most effective form of emergency contraception for up to 5 days after unprotected sex or within 5 days of expected ovulation...
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Vasopharm's ronopternin (VAS203) will be evaluated for its safety and efficacy as the first patient is enrolled into the nostra phase III (NO Synthase in TRAumatic Brain Injury) trial – a clinical study to assess whether the drug can be used as a initial treatment for moderately to severely injured…
8 September 2016 | By Tornado Spectral Systems
Leading manufacturer of optical spectrometers and Raman spectroscopy systems to highlight innovative technologies at annual SciX conference...
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, at a compound annual growth rate of 8.5%,…
Market leaders in temperature controlled microscopy, Linkam Scientific Instruments, report on the use of their high temperature TS1500 stage for research into the properties of 2D materials...
7 September 2016 | By Wilshire Technologies
The virtues of vegetal- vs. animal-derived actives and excipients are well-known and need no elaboration...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The committee agreed the combination offers life extending benefit compared to vemurafenib alone, however compared to alternative treatments it is too expensive. About 1,000 people would have been eligible each year...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The combination of Galenica's Vifor Pharma business with Relypsa will create a significant player in cardio-renal care in the US and further strength...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Aeterna Zentaris signed an exclusive license agreement with affiliates of Orient EuroPharma for its lead anti-cancer compound, zoptrex, for the initial...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Gelesis, a biotechnology company focused on developing products to safely induce weight loss and improve glycaemic control, have appointed David Pass, PhD as Chief Operating Officer...
5 September 2016 | By Eppendorf
Within the EU Research and Innovation program Horizon 2020 the European Union is now funding the TECHNOBEAT research project with almost 6 million Euro...
